Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

ClinicalTrials.gov ID: NCT06333951

Public ClinicalTrials.gov record NCT06333951. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 6, 2026, 8:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

Study identification

NCT ID: NCT06333951
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Amgen; Industry
Enrollment: 500 participants

Conditions and interventions

Conditions

Interventions

Anvumetostat Drug
Carboplatin Drug
Paclitaxel Drug
Pembrolizumab Drug
Pemetrexed Drug
Sotorasib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 100 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 16, 2024
Primary completion: Oct 26, 2028
Completion: Oct 26, 2031
Last update posted: Apr 12, 2026

2024 – 2031

United States locations

U.S. sites: 26
U.S. states: 13
U.S. cities: 23

Facility	City	State	ZIP	Site status
Comprehensive Blood and Cancer Center	Bakersfield	California	93309	Recruiting
City of Hope National Medical Center	Duarte	California	91010	Terminated
City of Hope Orange County Lennar Foundation Cancer Center	Duarte	California	91010	Terminated
Translational Research in Oncology US Inc, Trio Central Pharmacy	Los Angeles	California	90095	Recruiting
University of California Irvine	Orange	California	92868-3217	Recruiting
University of California Los Angeles	Santa Monica	California	90404	Recruiting
Rocky Mountain Cancer Centers	Denver	Colorado	80218	Recruiting
Eastern Connecticut Hematology and Oncology Associates	Norwich	Connecticut	06360	Terminated
HealthPartners Institute	Saint Paul	Minnesota	55102	Recruiting
Saint Lukes Hospital of Kansas City	Kansas City	Missouri	64111	Terminated
Comprehensive Cancer Centers of Nevada	Las Vegas	Nevada	89169	Terminated
Roswell Park Cancer Institute	Buffalo	New York	32224	Recruiting
New York University Grossman School of Medicine	New York	New York	10016	Recruiting
Perlmutter Cancer Center at New York University Langone Hospital----Long Island	New York	New York	10016	Recruiting
Upstate University Hospital	Syracuse	New York	13210	Recruiting
Hightower Clinical	Oklahoma City	Oklahoma	73102	Recruiting
Fox Chase Cancer Center	Philadelphia	Pennsylvania	19111	Recruiting
University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania	15232	Recruiting
University of Tennessee Medical Center Knoxville	Knoxville	Tennessee	37920	Recruiting
United States Oncology Regulatory Affairs Corporate Office	Nashville	Tennessee	37203	Recruiting
Texas Oncology - Dallas Fort Worth	Dallas	Texas	75246	Terminated
US Oncology Research Investigational Products Center	Dallas	Texas	75246	Recruiting
Oncology Consultants Cancer Center	Houston	Texas	77030	Terminated
Texas Oncology Northeast Texas	Tyler	Texas	75702	Recruiting
Virginia Cancer Specialists PC	Fairfax	Virginia	22031	Recruiting
Northwest Medical Specialties, PLLC	Tacoma	Washington	98405	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 57 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06333951, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 12, 2026 · Synced May 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06333951 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →